Login to Your Account



Sage comes up flat in SRSE phase III, but 'understanding' gained

By Marie Powers
News Editor

Tuesday, September 12, 2017

Sage Therapeutics Inc. sought to emphasize the lessons learned and increased understanding from the top-line readout of its first phase III trial, which assessed brexanolone (SAGE-547) in patients with super-refractory status epilepticus, or SRSE.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription